Clinically oriented immune heterogeneity in prostate cancer: emerging targets and strategies
Prostate cancer (PCa) has long been viewed as an immunologically “cold” malignancy because immune checkpoint inhibitors (ICIs) show limited benefit in unselected patients, particularly after progression to metastatic castration-resistant PCa (mCRPC) or…